A Prospective, Randomized, Open-label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus in Combination With Mealtime Insulin Lispro in Adult Patients With Type 1 Diabetes Mellitus is a PHASE3 clinical asset sponsored by Eli Lilly and Company in Diabetes Mellitus, Type 1. SEO and diligence focus: LY2963016, Lantus, Insulin Lispro, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.